Monte Rosa Therapeutics AG

Pioneering Therapies for Cancer and Beyond

Every cell has evolved sophisticated machinery to regulate the expression and function of proteins by degradation. This elaborate mechanism involves the controlled ubiquitination of protein substrates by E3 ligase complexes.

Using rationally designed small molecule degraders (also known as molecular glues) our goal is to hijack this natural process and redirect the degradation machinery to specific disease-causing proteins.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No milestones

No Jobs

No videos and documents

No Awards

Monte Rosa Therapeutics AG

Pioneering Therapies for Cancer and Beyond

Headquarter:
Basel

Foundation Date:
April 2018

Technology:

  • Biotech